Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity

Cytokine and Growth Factor Reviews

Volumn 8, Issue 1, 1997, Pages 21-43

  Pepper, Michael S ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cytokine; Development; Endothelium; Vascular biology

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL; BLOOD VESSEL; BLOOD VESSEL WALL; EMBRYOLOGY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0031106404     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(96)00048-2     Document Type: Short Survey

References (242)

1. Risau W, Flamme I. Vasculogenesis. A Rev Cell Dev Biol 1995, 11, 73-91.
2. Folkman J. Clinical applications of research on angiogenesis. New Engl J Med 1995, 333, 1757-1763.
3. Wagner RC. Endothelial cell embryology and growth. Adv Microcirc 1980, 9, 45-75.
4. Dieterlen-Lièvre F. La genèse du système sanguin chez l'embryon. La Recherche 1993, 254, 528-534.
5. Wilting J, Brand-Saberi B, Kurz H, Christ B. Development of the embryonic vascular system. Cell Molec Biol Res 1995, 41, 219-232.
6. Pepper MS. Positive and negative regulation of angiogenesis: from cell biology to the clinic. Vasc Med 1997, 1, 253-266.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995, 1, 149-153.
9. O'Reilly MS, Holmgren, L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nature Med 1996, 2, 689-692.
10. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest 1967, 17, 738-743.
11. Schwartz SM, Benditt EP. Aortic endothelial cell replication I. Effects of age and hypertension in the rat. Circ Res 1977, 41, 248-255.
12. Hobson B, Denekamp J. Endothelial proliferation in tumors and normal tissues: continuous labelling studies. Br J Cancer 1984, 49, 405-413.
13. Bouck N. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 1990, 2, 179-185.
14. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991, 113, 981-986.
15. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13, 18-32.
16. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146, 1029-1039.
17. Christofori G. The role of fibroblast growth factors in tumour progression and Angiogenesis. In Bicknell R, Lewis CE, Ferrara N, eds. Tumour Angiogenesis. Oxford, Oxford University Press, in press.
18. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
19. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 1994, 367, 576-579.
20. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W. Ullrich A, Strawn LM. Dominant negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56, 1615-1620.
21. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995, 92, 10,457-10,461.
22. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380, 435-439.
23. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380, 439-442.
24. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996, 93, 4851-4856.
25. Pepper MS, Mandriota S, Vassalli J-D, Orci L, Montesano R. Angiogenesis regulating cytokines: activities and interactions. Curr Top Microbiol Immunol 1996, 213/II, 31-67.
26. Montesano R, Vassalli J-D, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986, 83, 7297-7301.
27. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189, 824-831.
28. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987, 235, 442-447.
29. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. A Rev Physiol 1991, 53, 217-239.
30. Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996, 15, 149-151.
31. Miyazono K, Ichijo H, Heldin C-H. Transforming growth factor-β: latent forms, binding proteins and receptors. Growth Factors 1993, 8, 11-22.
32. Massagué J, Attisano L, Wrana JL. The TGF-β family and its composite receptors. Trends Cell Biol 1994, 4, 172-178.
33. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994, 8, 133-146.
34. Attisano L, Wrana JL, López-Casillas F, Massagué J. TGF-β receptors and actions. Biochim Biophys Acta 1994, 1222, 71-80.
35. Derynck R. TGF-β-receptor mediated signalling. Trends Bioehem Sci 1994, 19, 548-553.
36. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β-receptor. Nature 1994, 370, 341-347.
37. Yingling JM, Wang XF, Bassing CH. Signaling by the transforming growth factor-β receptors. Biochim Biophys Acta 1995, 1242, 115-136.
38. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-β. Am Rev Resp Dis 1989, 140, 1126-1128.
39. RayChaudhury A, D'Amore PA. Endothelial cell regulation by transforming growth factor-beta. J Cell Biochem 1991, 47, 224-229.
40. Madri JA, Kocher O, Merwin JR, Bell L, Tucker A, Basson CT. Interactions of vascular cells with transforming growth factors β. Ann NY Acad Sci 1990, 593, 243-258.
41. Madri JA, Bell L, Merwin JR. Modulation of vascular cell behavior by transforming growth factors β. Molec Reprod Dev 1992, 32, 121-126.
42. Akhurst RJ, Lehnert SA, Faissner AJ, Duffie E. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990, 108, 645-656.
43. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annuziata N, Doetschman T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992, 359, 693-699.
44. Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor β1 null mutation in mice causes excessive inflammatoy response and early death. Proc Natl Acad Sci USA 1993, 90, 770-774.
45. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculoenesis in transforming growth factor-β1 knock out mice. Development 1995, 121, 1845-1854.
46. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. Maternal rescue of transforming growth factor-β1 null mice. Science 1994, 264, 1936-1938.
47. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factors Rev 1996, 7, 93-102.
48. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β in patients with invasive prostate cancer. Nature Med 1995, 1, 282-283.
49. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995, 89, 45-48.
50. Plate KH. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metastasis Rev 1996, 15, 237-240.
51. Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye M, Oda Y, Kikuchi H, Hatanaka M. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990, 87, 5710-5714.
52. Samoto K, Ibezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995, 55, 1189-1193.
53. Krupinski J, Kumar P, Kumar S, Kaluza J. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 1996, 27, 852-857.
54. Gorden DL, Mandriota SJ, Montesano R, Orci L, Pepper MS. Vascular endothelial growth factor is increased in devascularized rat islets of Langerhans in vitro. Transplantation (in press).
55. Dissen GA, Lara HE, Fahrenbach WH, Costa ME, Ojeda SR. Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression. Endocrinology 1994, 134, 1146-1154.
56. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
57. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269, 4355-4359.
58. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 270, 19,761-19,766.
59. Fulanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts. J Invest Dermatol 1991, 97, 634-637.
60. Sakuda H, Nakashima Y, Kuriyama S, Sueishi K. Media conditioned by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship of transforming growth factor-β1. Am J Pathol 1992, 141, 1507-1516.
61. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 1995, 268, C1362-C1368.
62. Frank S, Madlener M, Werner S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 1996, 271, 10,188-10,193.
63. Auerbach R, Kubai L, Knighton D, Folkman J. A simple procedure for the long term cultivation of chick embryos. Dev Biol 1974, 41, 391-394.
64. Ausprunk DH, Knighton DR, Folkman J. Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Am J Pathol 1975, 79, 597-610.
65. Gimbrone MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974, 52, 413-427.
66. Andrade SP, Fan TPD, Lewis GP. Quantitative in vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol 1987, 68, 755-766.
67. Sprugel KH, McPherson JM, Clowes AW, Ross R. Effects of growth factors in viro. I. Cell ingrowth into porous subcutaneous chambers. Am J Pathol 1987, 129, 601-613.
68. Fajardo LF, Kowalski J, Kwan HH, Prionas SD, Allison AC. The disc angiogenesis system. Lab Invest 1988, 58, 718-724.
69. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992, 67, 519-528.
70. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad Sci USA 1986, 83, 4167-4171.
71. Frank JM, Kaneko S, Joels C, Tobin GR, Banis JC, Barker JH. Microcirculation research, angiogenesis, and microsurgery. Microsurgery 1994, 15, 399-404.
72. Rubbia-Brandt L, Sappino AP, Gabbiani G. Locally applied GM-CSF induces the accumulation of α-smooth muscle actin containing myofibroblasts. Virchows Arch B Cell Pathol 1991, 60, 73-82.
73. Yang EY, Moses HL. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990, 111, 731-741.
74. Phillips GD, Whitehead RA, Knighton DR. Inhibition by methylprednisolone acetate suggests an indirect mechanism for TGF-β induced angiogenesis. Growth Factors 1992, 6, 77-84.
75. Phillips GD, Whitehead RA, Stone AM, Ruebel MW, Goodkin ML, Knighton DR. Transforming growth factor beta (TGF-β) stimulation of angiogenesis: an electron microscopic study. J. Submicrosc Cytol Pathol 1993, 25, 149-155.
76. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A. Platelet-derived growth factor (BB homodimer), transforming growth factor-β1, and basic fibroblast growth factor in dermal wound healing. Am J Pathol 1992, 140, 1375-1388.
77. Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 1996, 74, 600 608.
78. Koh GY, Kim SJ, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA sythesis. J Clin Invest 1995, 95, 114-121.
79. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth factor-β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992, 1137, 189-196.
80. Ueki N, Ohkawa T, Yokoyama Y, Maeda J, Kawai Y, Ikeda T, Amuro Y, Hada T, Higashino K. Potentiation of metastatic capacity by transforming growth factor-β1 gene transfection. Jpn J Cancer Res 1992, 84, 589-593.
81. Dong QG, Graziani A, Garlanda C, Wainstok de Calmanovici R, Arese M, Soldi R, Vecchi A, Mantovani A, Bussolino F. Anti-tumor activity of cytokines against opportunistic vascular tumors in mice. Int J Cancer 1996, 65, 700-708.
82. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993, 90, 10,759-10,763.
83. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen L, Roberts AB, Smith GH, Merlino G. Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. Eur Molec Biol Org J 1993, 12, 1835-1845.
84. Pierce DF, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BLM, Moses H. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev 1993, 7, 2308-2317.
85. Pierce DF, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ, Moses H. Mammary tumor suppression by transforming growth factor-β1 transgene expression. Proc Natl Acad Sci USA 1995, 92, 4254-4258.
86. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995, 92, 2572-2576.
87. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996, 74, 991-1003.
88. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am J Pathol 1995, 147, 53-67.
89. Sellheyer K, Bickenbach JR, Rothnagel JA, Bundman D, Longley MA, Krieg T, Roche NS, Roberts AB, Roop DR. Inhibition of skin development by overexpression of transforming growth factor β1 in the epidermis of transgenic mice. Proc Natl Acad Sci USA 1993, 90, 5237-5241.
90. Cui W, Fowlis DJ, Cousins FM, Duffie E, Bryson E, Balmain A, Akhurst RJ. Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev 1995, 9, 945-955.
91. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996, 88, 531-542.
92. Zhou L, Dey CR, Wert SE, Whitsett JA. Arrested lung morphogenesis in transgenic mice bearing an SC-C-TGF-β1 chimeric gene. Dev Biol 1996, 175, 227-238.
93. Lee M-S, Gu D, Feng L, Curriden S, Arnush M, Krahl T, Gurushanthaiah D, Wilson C, Loskutoff DE, Fox H, Sarvetnick N. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-β1. Am J Pathol 1995, 147, 42-52.
94. Sanvito F, Nichols A, Herrera P-L, Huarte J, Wohlwend A, Vassalli J-D, Orci L, TGF-β 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-α, triggers insulin-dependent diabetes. Biochem Biophys Res Commun 1995, 217, 1279-1286.
95. Pierce GF, Mustoe TA, Lingelbach, J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. Platelet-derived growth factor and transforming growth factor-β enhance tissue repair activities by unique mechanisms. J Cell Biol 1989, 109, 429-440.
96. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, Kolasinski SL, Weissman G. Transforming growth factor β1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci USA 1991, 88, 6805-6809.
97. Wahl SM, Hunt DA, Wakefield LA, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type β induces monocyte chemataxis and growth factor production. Proc Natl Acad Sci USA 1987, 84, 5788-5792.
98. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J Exp Med 1987, 165, 251-256.
99. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988, 157, 793-800.
100. McCartney-Francis N, Mizel D, Wong H, Wahl L, Wahl S. TGF-β regulates production of growth factors and TGF-β by human peripheral blood monocytes. Growth Factors 1990, 4, 27-35.
101. Dolecki GJ, Connolly DT. Effects of a variety of cytokines and inducing agents on vascular permeability factor mRN A levels in U937 cells. Biochem Biophys Res Commun 1991, 180, 572-578.
102. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90, 649-652.
103. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and endothelial cells. J Biol Chem 1994, 269, 6271-6274.
104. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Lett 1996, 102, 209-215.
105. Kvanta A. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res 1995, 14, 1015-1020.
106. Chantry D, Turner M, Abney M, Abney E, Feldmann M. Modulation of cytokine production by transforming growth factor-β. J Immunol 1989, 142, 4295-4300.
107. Pertovaara L, Saksela O, Alitalo K. Enhanced bFGF gene expression in response to transforming growth factor-β stimulation of AKR-2B cells. Growth Factors 1993, 9, 81-86.
108. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980, 288, 551-555.
109. Maciag T, Kadish J, Wilkins L, Stemerman MB, Weinstein R. Organizational behaviour of human umbilical vein endothelial cells. J Cell Biol 1982, 94, 511-520.
110. Madri JA, Williams SK. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 1983, 97, 153-165.
111. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983, 97, 1648-1652.
112. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985, 42, 469-477.
113. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988, 107, 1589-1598.
114. Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by transforming growth factor-β depends on the composition and organization of the extracellular matrix. J Cell Biol 1988, 106, 1357-1384.
115. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirements for basic fibroblast growth factor-induced proteases. J Cell Biol 1989, 108, 671-682.
116. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 1990, 63, 115-122.
117. Iruela-Arispe ML, Hasselaar P, Sage H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab Invest 1991, 64, 174-186.
118. Vernon RB, Lara SL, Drake CJ, Iruela-Arispe ML, Angello JC, Little CD, Wight TN, Sage EH. Organized type I collagen influences endothelial patterns during "spontaneous angiogenesis in vitro": planar cultures as models of vascular development. In Vitro Cell Dev Biol 1995, 31, 120-131.
119. Madri JA, Basson MD. Extracellular matrix-cell interactions: dynamic modulators of cell, tissue and organism structure and function. Lab Invest 1992, 66, 519-521.
120. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type β-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 1986, 138, 476-482.
121. Fràter-Schröder M, Müller G, Birchmeier W, Böhlen P. Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986, 137, 295-302.
122. Heimark RL, Twardzik DR, Schwartz SM. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science 1986, 233, 1078-1080.
123. Müller G, Behrens J, Nussbaumer U, Böhlen P, Birchmeier W. Inhibitory action of transforming growth factor-β on endothelial cells. Proc Natl Acad Sci USA 1987, 84, 5600-5604.
124. Takehara K, LeRoy EC, Grotendorst GR. TGF-β inhibition of endothelial cell proliferation: alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression. Cell 1987, 49, 415-422.
125. Madri JA, Reidy MA, Kocher O, Bell L. Endothelial cell behavior after denudation injury is modulated by transforming growth factor-β1 and fibronectin. Lab Invest 1989, 60, 755-765.
126. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989, 86, 4544-4548.
127. Bensaid M, Malecaze F, Bayard F, Tauber JP. Opposing effects of basic fibroblast growth factor and transforming growth factor-β on the proliferation of cultured bovine retinal capillary endothelial (BREC) cells. Exp Eye Res 1989, 48, 791-799.
128. Segarini PR, Rosen DM, Seydin SM. Binding of transforming growth factor-β to cell surface proteins varies with cell type. Molec Endocr 1989, 3, 261-272.
129. Fafeur V, Terman BI, Blum J, Böhlen P. Basic FGF treatment of endothelial cells down-regulates the 85-KDa TGFβ receptor subtype and decreases the growth inhibitory response to TGF-β1. Growth Factors 1990, 3, 237-245.
130. Fafeur V, O'Hara B, Böhlen P. A glycosylation-deficient endothelial cell mutant with modified responses to transforming growth factor-β and other growth inhibitory cytokines: evidence for multiple growth inhibitory signal transduction pathways. Molec Biol Cell 1993, 4, 135-144.
131. Merwin JR, Anderson JM, Kocher O, van Itallie CM, Madri JA. Transforming growth factor-β1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 1990, 142, 117-128.
132. Merwin JR, Newman W, Beall LD, Tucker A, Madri J. Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro. Am J Pathol 1991, 138, 37-51.
133. Merwin JR, Roberts A, Kondaiah P, Tucker A, Madri J. Vascular cell responses to TGF-β3 mimick those of TGF-β1 in vitro. Growth Factors 1991, 5, 149-158.
134. Mooradian DL, Diglio CA. Effects of epidermal growth factor and transforming growth factor-β1 on rat heart endothelial cell anchorage-dependent and -independent growth. Exp Cell Res 1990, 186, 122-129.
135. Newton LK, Yung WKA, Pettigrew LC, Steck PA. Growth regulatory activities of endothelial cell extracellular matrix: mediation by transforming growth factor-β. Exp Cell Res 1990, 190, 127-132.
136. Coomber BL. Cytoskeleton in TGF-β-and bFGF-modulated endothelial monolayer repair. Exp Cell Res 1991, 194, 42-47.
137. Eisenstein R, Grant-Bertacchini D. Growth inhibitory activities in avascular tissues are recognized by anti-transforming growth factor β antibodies. Curr Eye Res 1991, 10, 157-162.
138. Sutton AB, Canfield AE, Schor SL, Grant ME, Schor AM. The response of endothelial cells to TGF-β1 is dependent on cell shape, proliferative state and the nature of the substratum. J Cell Sci 1991, 99, 777-787.
139. Das SK, White AC, Fanburg BL. Modulation of transforming growth factor-β1 antiproliferative effects on endothelial cells by cysteine, cystine, and N-acetylcysteine. J Clin Invest 1992, 90, 1649-1656.
140. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast factor-induced activation of latent transforming growth factor β in endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992, 118, 901-909.
141. Hirai R, Kaji K. Transforming growth factor β1-specific binding proteins on human vascular endothelial cells. Exp Cell Res 1992, 201, 119-125.
142. Klein-Soyer C, Archipoff G, Beretz A, Cazenave JP. Opposing effects of heparin with TGF-β or aFGF during repair of a mechanical wound of human endothelium. Influence of cAMP on cell migration. Biol Cell 1992, 75, 155-162.
143. Magyar-Lehmann S, Böhlen P. Purification of platelet derived endothelial cell growth inhibitor and its characterization as transforming growth factor-β type 1. Experientia 1992, 48, 374-379.
144. Qian SW, Burmester JK, Merwin JR, Madri JA, Sporn MB, Roberts AB. Identification of a structural domain that distinguishes the action of the type 1 and 2 isoforms of transforming growth factor β on endothelial cells. Proc Natl Acad Sci USA 1992, 89, 6290-6294.
145. D'Amore PA, Smith SR. Growth factor effects on cells of the vascular wall: a survey. Growth Factor 1993, 8, 61-75.
146. Gajdusek CM, Luo Z, Mayberg MR. Basic fibroblast growth factor and transforming growth factor beta-1: synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993, 157, 133-144.
147. Iruela-Arispe ML, Sage EH. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-β1. J Cell Biochem 1993, 52, 414-430.
148. RayChaudhury A, Frazier WA, D'Amore PA. Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta. J Cell Sci 1994, 107, 39-46.
149. Choi ME, Ballermann BJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors. J Biol Chem 1995, 270, 21,144-21,150.
150. Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL, Madri JA. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 1995, 270, 13,567-13,572.
151. Sankar S, Mahooti-Brooks N, Bensen L, McCarthy TL, Centrella M, Madri JA. Modulation of transforming growth factor β receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1996, 97, 1436-1446.
152. Taipale J, Kseki-Oja J. Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-β1. J Biol Chem 1996, 271, 4342-4348.
153. Takashima S, Klagsbrun M. Inhibition of endothelial cell growth by macrophage-like U-937 cell-derived oncostatin M, leukemia inhibitory factor, and transforming growth factor β1. J Biol Chem 1996, 271, 24,901-24,906.
154. Myoken Y, Kan M, Sato GH, McKeehan WL, Sato D. Bifunctional effects of transforming growth factor-β (TGF-β) on endothelial cell growth correlate with phenotypes of TGF-β binding sites. Exp Cell Res 1990, 191, 299-304.
155. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988, 107, 1199-1205.
156. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol 1989, 109, 309-315.
157. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990, 111, 757-763.
158. Bell L, Madri JA. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circ Res 1989, 65, 1057-1065.
159. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994, 55, 419-434.
160. Kocher O, Kennedy SP, Madri JA. Alternative splicing of endothelial cell fibronectin mRNA in the IIICS region. Am J Pathol 1990, 137, 1509-1524.
161. Basson CT, Kocher O, Basson MD, Asis A, Madri JA. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-β1 correlates with reciprocal effects on cell migration. J Cell Physiol 1992, 153, 118-128.
162. Enenstein J, Waleh NS, Kramer RH. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992, 203, 499-503.
163. 3 integrin complex on microvascular endothelial cells. J Invest Dermatol 1994, 103, 295-299.
164. Frank R, Adelmann-Grill BC, Herrmann K, Haustein UF, Petri JB, Heckmann M. Transforming growth factor-β controls cell-matrix interaction of microvascular dermal endothelial cells by downregulation of integrin expression. J Invest Dermatol 1996, 106, 36-41.
165. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987, 105, 957-963.
166. Pepper MS, Belin D, Montesano R, Orci L, Vassalli J-D. Transforming growth factor beta-1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990, 111, 743-755.
167. Sawdey MS, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J Biol Chem 1989, 264, 10,396-10,401.
168. Pepper MS, Montesano R, Orci L, Vassalli J-D. Plasminogen activator inhibitor-1 is induced in microvascular endothelial cells by a chondrocyte-derived transforming growth factor-beta. Biochem Biophys Res Commun 1991, 176, 633-638.
169. Fujii S, Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991, 83, 645-651.
170. Slivka SR, Loskutoff DJ. Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of
171. Flaumenhaft R, Rifkin DB. Cell density effects of TGF-β demonstrated by a plasminogen activator-based assay for TGF-β. J Cell Physiol 1992, 152, 48-55.
172. Tada K, Fukunaga T, Wakabayashi Y, Masumi S, Sato Y, Izumi H, Kohno K, Kuwano M. Inhibition of tubular morphogenesis in human microvascular endothelial cells by co-culture with chondrocytes and involvement of transforming growth factor-β: a model for avascularity in human cartilage. Biochim Biophys Acta 1994, 1201, 135-142.
173. Kocher O, Madri JA. Modulation of actin mRNAs in cultured vascular cells by matrix components and TGF-β1. In Vitro Cell Dev Biol 1989, 25, 424-434.
174. Arciniegas E, Sutton AB, Allen TD, Schor AM. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 1992, 103, 521-529.
175. Brown MR, Vaughan J, Jimenez LL, Vale W, Baird A. Transforming growth factor-β: role in mediating serum-induced endothelin production by vascular endothelial cells. Endocrinology 1991, 129, 2355-2360.
176. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-β1. Arterioscler Thromb Vasc Biol 1995, 15, 1255-1261.
177. Daniel TO, Gibbs, VC, Milfay DF, Williams LT. Agents that increase cAMP accumulation block endothelial c-sis induction by thrombin and transforming growth factor-β. J Biol Chem 1987, 262, 11,893-11,896.
178. Starksen NF, Harsh GR, Gibbs VC, Williams LT. Regulated expression of the platelet-derived growth factor A chain gene in microvascular endothelial cells. J Biol Chem 1987, 262, 14,381-14,384.
179. Kavanaugh WM, Harsh GR, Starksen NF, Rocco CM, Williams LT. Transcriptional regulation of the A and B chains of platelet-derived growth factor in microvascular endothelial cells. J Biol Chem 1988, 263, 8470-8472.
180. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J Immunol 1993, 150, 4494-4503.
181. Ohji T, Urano H, Shirahata A, Yamagishi M, Higashi K, Gotoh S, Karasaki Y. Transforming growth factor beta1 and beta2 induce down-modulation of thrombomodulin in human umbilical vein endothelial cells. Thromb Haemost 1995, 5, 812-818.
182. Mandriota SJ, Menoud PA, Pepper MS. Transforming growth factor-β1 downregulates vascular endothelial growth factor receptor-2/flk-1 expression in vascular endothelial cells. J Biol Chem 1996, 271, 11,500-11,505.
183. Das SK, Fanburg BL. TGF-β1 produces a "prooxidant" effect on bovine pulmonary artery endothelial cells in culture. Am J Physiol 1991, 261, L249-L254.
184. Lombardi T, Montesano R, Furie MB, Silverstein SC, Orci L. In vitro modulation of endothelial fenestrae: opposing effects of retinoic acid and transforming growth factor β. J Cell Sci 1988, 91, 313-318.
185. Pepper MS, Vassalli J-D, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993, 204, 356-363.
186. Etoh T, Takehara K, Igarashi A, Ishibashi Y. The effects of various growth factors on endothelial cell survival in vitro. Biochem Res Commun 1989, 162, 1010-1016.
187. Tsukada T, Eguchi K, Migita K, Kawabe Y, Kawakami A, Matsuoka N, Takashima H, Mizokami A, Nagataki S. Transforming growth factor β1 induces apoptotic cell death in cultured human umbilical vein endothelial cells with down-regulated expression of bc 1-2. Biochem Biophys Res Commun 1995, 210, 1076-1082.
188. Pepper MS, Montesano R, Vassalli J-D, Orci L. Chondrocytes inhibit endothelial sprout formation in vitro: evidence for the involvement of a transforming growth factor-beta. J Cell Physiol 1991, 146, 170-179.
189. Okamura K, Morimoto A, Hamanaka R, Ono M, Kohno K, Uchida Y, Kuwano M. A model system for tumor angiogenesis involvement of transforming growth factor-α in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem Biophys Res Commun 1992, 186, 1471-1479.
190. Kuzuya M, Kinsella JL. Reorganization of endothelial cord-like structures on basement membrane complex (Matrigel). Involvement of transforming growth factor β1. J Cell Physiol 1994, 161, 267-276.
191. Montesano R, Pepper MS, Vassalli J-D, Orci L. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. J Cell Physiol 1987, 132, 509-516.
192. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis: Cell Differ Dev 1990, 32, 319-328.
193. Pepper MS, Montesano R, Mandriota S, Orci L, Vassalli J-D. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996, 49, 138-162.
194. 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990, 60, 849-859.
195. Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 1996, 134, 1551-1562.
196. Antonelli-Orlidge A, Smith SR, D'Amore PA. Influence of pericytes on capillary endothelial cell growth. Am Rev Respir Dis 1989, 140, 1129-1131.
197. Rifkin DB, Moscatelli D, Flaumenhaft R, Sato Y, Saksela O, Tsuboi R. Mechanisms controlling the extracellular activity of basic fibroblast growth factor and transforming growth factor β. Ann NY Acad Sci 1991, 614, 250-258.
198. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987, 105, 1455-1462.
199. Nehls V, Drenckhahn D. The versality of microvascular pericytes: from mesenchyme to smooth muscle? Histochemistry 1993, 99, 1-12.
200. Oshima M, Oshima H, Taketo MM. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996, 179, 297-302.
201. Lawler S, Candia AF, Ebner R, Shum L, Lopez AR, Moses HL, Wright CVE, Derynck R. The murine type II TGF-β receptor has a coincident embryonic expression and binding preference for TGF-β1. Development 1994, 120, 165-175.
202. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangectasia. New Engl J Med 1995, 333, 918-924.
203. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangectasia type 1. Nature Genetics 1994, 8, 345-351.
204. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990, 265, 8361-8364.
205. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992, 267, 19,027-19,030.
206. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon S-J, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous MEM, Marchuk DA. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangectasia type 2. Nature Genetics 1996, 13, 189-195.
207. Attisano L, Carcamo J, Ventura F, Weis FMB, Massagué J, Wrana JL. Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75, 671-680.
208. Barnett JV, Moustakas A, Lin W, Wang X-F, Lin HY, Galper JB, Maas RL. Cloning and developmental expression of the chick type II and type III TGFβ receptors. Dev Dynamics 1994, 199, 12-27.
209. Matsuura H, Myokai F, Arata J, Noji S, Taniguchi S. Expression type II transforming growth factor-beta receptor mRNA in human skin, as revealed by in situ hybridization. J Dermatol Sci 1994, 8, 25-32.
210. Iseki S, Osumi-Yamashita N, Miyazono K, Franzén P, Ichijo H, Ohtani H, Hayashi Y, Eto K. Localization of transforming growth factor-β type I and type II receptors in mouse development. Exp Cell Res 1995, 219, 339-347.
211. Wang Y-Q, Sizeland A, Wang X-F, Sassoon D. Restricted expression of type-II TGFβ receptor in murine embryonic development suggests a central role in tissue remodeling and CNS patterning. Mechanisms Dev 1995, 52, 275-289.
212. Zhao Y, Young SL. Expression of transforming growth factor-β type II receptor in rat lung is regulated during development. Am J Physiol 1995, 269, L419-L426.
213. Roy SK, Kole AR. Transforming growth factor-β receptor type II expression in the hamster ovary: cellular site(s), biochemical properties, and hormonal regulation. Endocrinology 1995, 136, 4610-4620.
214. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. J Clin Invest 1991, 88, 1346-1353.
215. Fearns C, Samad F, Loskutoff DJ. Synthesis and localization of PAI-1 in the vessel wall. In Vadas M, Harlan J, eds. Vascular Control of Hemostasis. Advances in Vascular Biology. Camberwell, Victoria, Australia, Gordon and Breach Publishers, 1996, 207-226.
216. Dickson K, Philip A, Warshawsky H, O'Connor-McCourt M, Bergeron JJM. Specific binding of endocrine transforming growth factor-β1 to vascular endothelium. J Clin Invest 1995, 95, 2539-2554.
217. Ge AZ, Butcher EC. Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-β ligand. Gene 1994, 138, 201-206.
218. St-Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology 1994, 134, 2645-2657.
219. Kumar P, Wang JM, Bernabeu C. CD 105 and angiogenesis. J Pathol 1996, 178, 363-366.
220. Morello JP, Plamondon J, Meyrick B, Hoover R, O'Connor-McCourt MD. Transforming growth factor-β receptor expression on endothelial cells: heterogeneity of type III receptor expression. J Cell Physiol 1995, 165, 201-211.
221. Jennings JC, Mohan S, Linkhart TA, Widstrom TA, Baylink DJ. Comparison of the biological actions of TGF beta-1 and TGF beta-2: differential activity in endothelial cells. J Cell Physiol 1988, 137, 167-172.
222. Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massagué J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 1990, 265, 20,533-20,538.
223. Burmester JK, Qian SW, Roberts AB, Huang A, Amatayakul-Chantler S, Suardet L, Odartchenko N, Madri JA, Sporn MB. Characterization of distinct functional domains of transforming growth factor β. Proc Natl Acad Sci USA 1993, 90, 8628-8632.
224. Chen R-W, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 1993, 260, 1335-1338.
225. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994, 8, 1875-1887.
226. 5 integrin-deficient mice. Development 1993, 119, 1093-1105.
227. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993, 119, 1079-1091.
228. Soriano P. Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev 1994, 8, 1888-1896.
229. Schatteman GC, Loushin C, Li T, Hart CE. PDGF-A is required for normal murine cardiovascular development. Dev Biol 1996, 176, 133-142.
230. Gronwald RGK, Seifert RA, Bowen-Pope DF. Differential regulation of expression of two platelet-derived growth factor receptor subunits by transforming growth factor-β. J Biol Chem 1989, 264, 8120-8125.
231. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990, 63, 515-524.
232. Casscells W. Smooth muscle cell growth factors. Progr Growth Factor Res 1992, 3, 177-206.
233. Schwartz SM, deBlois D, O'Brien ERM. The intima. Soil for atherosclerosis and restenosis. Circ Res 1995, 77, 445-465.
234. Sporn MB, Roberts AB, Shull JH, Smith JM, Ward JM, Sodek J. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science 1983, 219, 1329-1331.
235. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science 1987, 237, 1333-1336.
236. Beck LS, Chen TL, Hirabayashi SE, Deguzman L, Lee WP, McFatridge LL, Xu Y, Bates RL, Ammann AJ. Accelerated healing of ulcer wounds in the rabbit ear by recombinant human transforming growth factor-β1. Growth Factors 1990, 2, 273-282.
237. Beck LS, Deguzman L, Lee WP, Xu Y, McFatridge LA, Amento EP. TGF-β1 accelerates wound healing: reversal of steroid-impaired healing in rats and rabbits. Growth Factors 1990, 5, 295-304.
238. Quaglino D, Nanney LB, Ditesheim JA, Davidson JM. Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin: incisional wound model: J Invest Dermatol 1991, 97, 34-42.
239. Quaglino D, Nanney LB, Kennedy R, Davidson JM. Transforming growth factor-β stimulates would healing and modulates extracellular matrix gene expression in pig skin: excisional wound model. Lab Invest 1990, 63, 307-319.
240. Zhao LL, Davidson JD, Wee SC, Roth SI, Mustoe TA. Effect of hyperbaric oxygen and growth factors on rabbit ear ischemic ulcers. Arch Surg 1994, 129, 1043-1049.
241. Roesel JF, Nanney LB. Assessment of differential cytokine effects on angiogenesis using an in vivo model of cutaneous wound repair. J Surg Res 1995, 58, 449-459.
242. Bonyadi M, Rusholme SAB, Cousins FM, Su HC, Biron CA, Farrell M, Akhurst RJ. Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genetics 1997, 15, 207-211.